Human Longevity was founded in 2013 by J. Craig Venter, Peter Diamandis, and Robert Hariri. The company has not officially endorsed a plan to participate in an IPO. These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Human Longevity is a genomics-based health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype, and clinical data. The company's mission is "to extend healthy human life by revolutionizing human health and transforming the practice of medicine." The company has acquired Cypher Genomics and DoctorsForMe. Human Longevity, based in San Diego, has raised $330 million in venture capital funding from investors including Emerging Technology Partners, Threshold, StartUp Health, OS Fund, Illumina Ventures, GE Ventures, Celgene, and Amino Capital. The company has not disclosed recent valuation information, but in 2018 Human Longevity reported a significant drop in valuation, falling from $1.6 billion to $310 million.

Register for Details

For more details on financing and valuation for Human Longevity, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Human Longevity

Forge green plus iconForge green minus icon

What is Human Longevity's IPO price?

The IPO price for Human Longevity will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Human Longevity?

Human Longevity is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Human Longevity shares pre-IPO?

If you own Human Longevity pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Human Longevity a publicly traded company?

Human Longevity is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Human Longevity's funding to date?

Human Longevity has raised $69.48MM to date.
Forge green plus iconForge green minus icon

When was Human Longevity founded?

Human Longevity was founded in 2013.

Who are Human Longevity's major investors?

GE Ventures
Draper Fisher Jurvetson
Amino Capital
Synthetic Genomics
StartUp Health

Human Longevity funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation

Series B-1 and B-2

$17.42MM raised $XXX.XX $XXX.XX

Series A-1 and A-2

$52.06MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jun 24, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.